The majority of the drugs approved by the FDA for treatment of cognitive symptoms in Alzheimer's disease (AD) patients are cholinesterase inhibitors and include drugs such as donepezil, galantamine, and rivastagimine. However, the tolerated doses of cholinesterase inhibitors, such as donepezil, produce only partial improvement in memory and can have severe GI side effects. Since these medications have to be taken for prolonged durations, the limited efficacy... Read More
Sep 17, 2015
Mouse Model Helps Accelerate Development of New Alzheimer's Therapies
